Sydbank: Lundbeck’s profit margin under pressure
Sydbank sees a rapidly declining profit margin for Lundbeck in the second quarter of the year compared with Q2 2011, but the bank remains optimistic about the share.
The declining sale of the antidepressant Lexapro in the US will have a significant impact on the coming Q2 financial statement from Lundbeck, add to that unforeseen costs for the announced organization restructuring, and it becomes clear that profit margins will be far from the numbers in the same period last year.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
.jpg&w=384&q=75){kind=logo}
